Our history timeline
Discover the moments that made us the company we are today
Biggest growth yet
- LUMICKS raised $93 million in series D funding.
- With 128 new hires – including 10 in key senior positions – we more than doubled in company size.
- Continued to empower researchers with more than 35 articles published in high-impact journals using LUMICKS’ technology.
- Rapid growth of z-Movi user base in immuno-oncology, with placements at elite academic and commercial institutions such as Harvard University, Oxford University, Fred Hutchinson Cancer Research Center, INmune Bio, and more.
- Installed C-Trap and m-Trap instruments in renowned institutes, including at VIB, Westlake University, TU Munich, and the University of Pittsburgh.
- Launched new services and initiatives tackling the full DSM experimental workflow from experimental design to data analysis
Image: Various publications using LUMICKS’ technology.
Discovering new parameters
- Launched z-Movi Cell Avidity Analyzer to the public and made first sales and collaborations with biotech companies (LAVA therapeutics, Glycostem, Leucid Bio) and academia.
- Installed C-Trap and m-Trap instruments in world-leading institutes in 4 continents: National Institutes of Health (NIH), Emory University, Technical University of Munich (TUM), RIKEN – Center for Brain Science in Japan, the National Centre for Biotechnology (CNB) in Spain, University of Chile and many more.
- Successfully adapted to the pandemic, and still hired 42 new LUMIs and grew to 130 employees.
- Established the first office in Beijing to serve the APR market.
- Launched DSM consumables line and Harbor script-sharing platform to make DSM analysis easier and more reproducible.
- Installed an ML-II (biosafety level 2) lab at the LUMICKS headquarters.
Image: The z-Movi® Cell Avidity Analyzer.
Onward and upward
- LUMICKS grew to over 100 employees, doubling that of the previous year.
- We moved our Amsterdam HQ from Vrije University to a vast 1750-meter-squared complex which we fit with 7 unique meeting rooms, advanced R&D facilities, and a dedicated area for seminars.
- Our grand reopening was inaugurated by Dutch minister van Engelshoven.
- Expanded the C-Trap with the Surface Assay Toolkit (SAT): unique assortment of new features to deliver ultra-stable surface arrays at the single-molecule level.
- More sales to key institutions worldwide: Universities of Munich, Tel Aviv, Vermont, Tianjin, Vanderbilt, NIH, and Albert Einstein College of Medicine.
Image: Microtubules imaged in real-time using the C-Trap optical tweezers correlated with widefield and label-free microscopy.
Expanding across new markets
- First sales in South America & Australia; new customers in TU Delft, University at Buffalo, Hong Kong University of Science and Technology, Semmelweis University, Ludwig Maxmillian University, and many more.
- LUMICKS grows to 55 people.
- Established the first Center for dynamic single-molecule drug research in partnership with AstraZeneca and the University of Cambridge.
- Entered the immunology market with z-Movi for Cell avidity measurements.
- Launched G2 product line & next-gen Bluelake software.
- Developed Surface Assay toolkit for use in cell biology.
Image: The LUMICKS team, end of 2018.
A global presence
- Sales to Imperial College London, Johns Hopkins University, University of Zurich and more.
- First Pharmaceutical Customers.
- 30% revenue from China.
- Opened LUMICKS’ first US Sales office in Boston, Massachusetts.
- Received series A funding.
- The company grew to 38 employees.
- Started investing in scale-up.
Image: The m-Trap® Optical Tweezers.
Key accounts and broadening technologies
- Sales to Rockefeller University, AMOLF, ShanghaiTech University, University of Göttingen.
- First Nature publication with data captured using C-Trap.
- Organic growth.
- Developed Acoustic Force Spectroscopy technology.
- First C-Trap installations in peer-reviewed journals.
- LUMICKS grew to 19 FTEs.
- Break even.
Image: Co-founder & CEO Olivier Heyning accepts the 2016 Young Start-up Award. Picture by Eric Brinkhorst
- First C-Trap sales following product introduction.
- BIOCEV Prague & MPI-CBG, the first two C-Trap users.
- 12 employees.
Image: The C-Trap® Optical Tweezers – Fluorescence Microscopy & Label-free Microsopy.
- First component sale to Harvard.
- License agreement.
- LUMICKS was founded.
Image: Co-founder Andrea Candelli demonstrating LUMICKS technology to State Secretary Sander Dekker.
The first steps
- The first patent filed.
- Publication in Nature on CTFM Technology.
- ERC Proof of Concept subsidy granted.